Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 27
Filtrar
1.
Int Immunopharmacol ; 68: 58-67, 2019 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-30612085

RESUMEN

OBJECTIVE: HSV-2 infection has increased significantly in recent years, which is closely associated with cervical cancer and HIV infection. The lack of success in vaccine development and the emergence of drug resistance to commonly used drugs emphasize the urgent need for alternative antivirals against HSV-2 infection. Arbidol (ARB) has been demonstrated to be a broad spectrum antiviral drug that exhibits immunomodulatory properties that affect the HSV-2 life cycle. This study investigated the efficacy and mechanism of ARB against HSV-2 in vivo and in vitro to further explore the clinical application of ARB. METHODS: The efficacy of ARB on HSV-2 infection in vitro was examined by CPE and MTT assays. A vaginitis model was established to monitor changes in histopathology and inflammatory cytokine (IL-2, IL-4, TNF-α and TGF-ß) expression by H&E staining and ELISA, respectively, and the efficacy of ARB was evaluated accordingly. Furthermore, flow cytometry was used to determine the ratio of CD4+/CD8+ T cells in the peripheral blood of the vaginitis animals. Considering the balance of efficacy and pharmacokinetics, ARB ointment was strictly prepared to observe formulation efficacy differences compared to the oral dosing form. RESULTS: The results showed that, in vitro, the TC50 and IC50 of ARB were 32.32 µg/mL and 4.77 µg/mL (SI = 6.82), respectively, indicating that ARB presents effective activity against HSV-2 in a dose-dependent manner. The results of the time-course assay suggested that 25 µg/mL ARB affected the late stage of HSV-2 replication. However, ARB did not inhibit viral attachment or cell penetration. The in vivo results showed that ARB ointment can improve the survival rate, prolong the survival time and reduce the reproductive tract injury in mice infected with HSV-2, regulate cytokine expression; and balance the CD4+ and CD8+ T lymphocyte ratio in the peripheral blood to participate in the regulation of immune response. CONCLUSION: ARB showed anti-HSV-2 activity in vitro in a dose-dependent manner and played a role in inhibiting the late replication cycle of the virus. The vaginitis model was successfully established, according to immunomodulation outcomes, responded better to ARB in ointment form than in oral form.


Asunto(s)
Antivirales/uso terapéutico , Herpes Simple/tratamiento farmacológico , Indoles/uso terapéutico , Vaginitis/tratamiento farmacológico , Animales , Antivirales/farmacología , Relación CD4-CD8 , Chlorocebus aethiops , Citocinas/inmunología , Modelos Animales de Enfermedad , Femenino , Herpes Simple/inmunología , Herpesvirus Humano 2/efectos de los fármacos , Herpesvirus Humano 2/fisiología , Indoles/farmacología , Ratones , Vaginitis/inmunología , Células Vero , Acoplamiento Viral/efectos de los fármacos , Internalización del Virus/efectos de los fármacos
2.
Bull Exp Biol Med ; 164(1): 75-79, 2017 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-29119394

RESUMEN

The effects of bone marrow multipotent mesenchymal stromal cells and their secretion products on the subpopulation composition of thymic and splenic lymphocytes were studied in female Wistar rats with experimental chronic inflammatory process in the internal genitals. Stromal cells and medium conditioned by these cells in different administration routes (intravenous or lymphotropic injection) produces different modulating effect on blood leukocyte count and on subpopulation composition of the splenic and thymic lymphocytes. The most manifest anti-inflammatory effect was observed after lymphotropic injection of multipotent mesenchymal stromal cells creating a high concentration and long persistence of the factors produced by these cells in the focus of inflammation.


Asunto(s)
Células Madre Mesenquimatosas/metabolismo , Bazo/patología , Timo/patología , Vaginitis/terapia , Animales , Células de la Médula Ósea/metabolismo , Células Cultivadas , Femenino , Recuento de Linfocitos , Trasplante de Células Madre Mesenquimatosas , Ratas Wistar , Bazo/inmunología , Linfocitos T/fisiología , Timo/inmunología , Vaginitis/inmunología
3.
Am J Reprod Immunol ; 75(2): 126-33, 2016 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-26773532

RESUMEN

PROBLEM: A wide variety of mediators are involved in inflammatory processes. However, the identity of those participating in vaginal immune responses has not been established. We correlated extracellular matrix metalloproteinase inducer (EMMPRIN), matrix metalloproteinase-8 (MMP-8), hyaluronan (HA), hyaluronidase-1 (Hyal-1), human ß-defensin-2 (hBD2), and neutrophil gelatinase-associated lipocalin (NGAL) concentrations with the extent of leukocyte infiltration into the vagina and suggest their participation in vaginal inflammation. METHODS OF STUDY: Vaginal fluid was obtained from 233 women seen at the outpatient clinic in the Department of Obstetrics and Gynecology at Campinas University, Brazil. The magnitude of vaginal inflammation was determined by the leukocyte count on vaginal smears and categorized as no inflammation (0 leukocytes/field), moderate inflammation (1-4 leukocytes/field), and intense inflammation (>4 leukocytes/field). Concentrations of EMMPRIN, MMP-8, HA, Hyal-1, hBD2, and NGAL were determined in vaginal fluid by ELISA. RESULTS: EMMPRIN, MMP-8, HA, hBD2, and NGAL concentration increased with elevated leukocyte numbers (P < 0.05), while Hyal-1 did not. EMMPRIN concentrations were correlated with HA and MMP-8 levels. CONCLUSION: EMMPRIN, MMP-8, HA, ß-defensin, and NGAL are elevated in women with vaginal inflammation.


Asunto(s)
Proteínas de Fase Aguda/inmunología , Basigina/inmunología , Ácido Hialurónico/inmunología , Lipocalinas/inmunología , Metaloproteinasa 8 de la Matriz/inmunología , Proteínas Proto-Oncogénicas/inmunología , Vaginitis/inmunología , beta-Defensinas/inmunología , Adulto , Femenino , Humanos , Hialuronoglucosaminidasa/inmunología , Leucocitos/inmunología , Lipocalina 2 , Adulto Joven
4.
Exp Clin Transplant ; 13 Suppl 1: 219-22, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25894158

RESUMEN

OBJECTIVES: Solid-organ transplant recipients are at increased risk of developing cancer including cervical cancer compared with woman in the general population, mostly due to long-term immunosuppressive therapy. The Papanicolaou smear remains the primary method of screening cervical pathology including preinvasive and invasive lesions. The objective of this study was to evaluate Pap smear findings in solid-organ transplant recipients, determine the prevalence of abnormal smears, and compare these patients with the general population. MATERIALS AND METHODS: We retrospectively examined 111 women patients who received liver or kidney transplant between January 1990 to December 2012 at Baskent University Ankara Hospital. Pap smear findings were compared with normal control patients matched for same age and technical procedure of cervical cytology. To selection of control patients, propensity score matching program was performed. All Pap smears were re-examined according to Bethesda 2001 criteria. RESULTS: In 111 transplant patients, 2 patients (1.8%) had atypical squamous cells of undetermined significance, 8 patients (7.2%) had low-grade squamous intraepithelial lesion, 15 patients (13.5%) had Candida infection, 2 patients (1.8%) had Trichomonas vaginalis, 1 patient (0.9%) had herpes simplex infection, 13 patients (11.7%) had bacterial vaginosis, 15 patients (13.5%) had reactive changes due to inflammation, and 18 patients (16.2%) had atrophy. When we compared our results with the control group, there were statistically significant differences (P ≤ .05) between the 2 groups in epithelial cell abnormalities (low-grade squamous intraepithelial lesion), Candida infection, bacterial vaginosis, and atrophy. CONCLUSIONS: Pap smear screening potentially may help recognize cervical preinvasive and invasive lesions. The risk of developing cervical intraepithelial neoplasia is greater in transplant recipients because of immunosuppressive therapy. The incidence of low-grade squamous intraepithelial lesion was significantly greater in transplant recipients than the general population. Intensive follow-up with Pap smear in transplant recipients is important in the early detection of these lesions.


Asunto(s)
Células Escamosas Atípicas del Cuello del Útero/patología , Trasplante de Riñón/efectos adversos , Trasplante de Hígado/efectos adversos , Prueba de Papanicolaou , Displasia del Cuello del Útero/patología , Neoplasias del Cuello Uterino/patología , Frotis Vaginal , Vaginitis/patología , Adolescente , Adulto , Células Escamosas Atípicas del Cuello del Útero/inmunología , Femenino , Hospitales Universitarios , Humanos , Huésped Inmunocomprometido , Inmunosupresores/efectos adversos , Persona de Mediana Edad , Clasificación del Tumor , Valor Predictivo de las Pruebas , Prevalencia , Puntaje de Propensión , Estudios Retrospectivos , Factores de Riesgo , Factores de Tiempo , Resultado del Tratamiento , Turquía/epidemiología , Neoplasias del Cuello Uterino/epidemiología , Neoplasias del Cuello Uterino/inmunología , Vaginitis/epidemiología , Vaginitis/inmunología , Adulto Joven , Displasia del Cuello del Útero/epidemiología , Displasia del Cuello del Útero/inmunología
5.
Contraception ; 87(6): 756-65, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23089047

RESUMEN

BACKGROUND: This study was conducted to evaluate the efficacy, safety and acceptability of a newly developed benzalkonium chloride (BZK) contraceptive gel which was compared to nonoxynol-9 (N-9) gel. STUDY DESIGN: A Phase II, multicenter, randomized, controlled study at three Chinese centers was conducted to compare 120 women who used BZK gel with 120 women who used N-9 gel for 6 months. Contraceptive efficacy was assessed by pregnancy rate, and safety was evaluated by adverse events report, gynecologic examination, Papanicolaou smears, leukorrhea test, and blood and urine tests. The acceptability was assessed through follow-up visit forms and a questionnaire at the 6-month visit. RESULTS: Net cumulative rates in the BZK group at 6 months were as follows: follow-up 100%, terminations 5.1%, pregnancy 1.7%, medical reasons 0% and fear of failure 3.4%. At 6 months, the rates in the N-9 group were as follows: follow-up 99.2%, terminations 9.4%, pregnancy 0.9%, medical reasons 2.5%, fear of failure 3.4% and other personal reasons 2.6%. No significant difference in pregnancy rate and termination rate between the two groups was found (p>.05). Seven cases in the BZK group (5.8%) complained about leukorrhagia and vaginal irritation symptoms (itching and burning) at 6 months, while 16 cases in the N-9 group (13.3%) had similar complaints (p<.05). This significant difference continued to exist until the 6-month visit. The general satisfaction rate for BZK gel use (72.8%) is significantly higher than that for N-9 gel (42.5%). CONCLUSION: The optimized BZK gel is comparable to N-9 gel in terms of contraceptive efficacy and safety, and may be more acceptable to Chinese users.


Asunto(s)
Compuestos de Benzalconio/administración & dosificación , Medicamentos sin Prescripción/administración & dosificación , Espermicidas/administración & dosificación , Adulto , Compuestos de Benzalconio/efectos adversos , China/epidemiología , Comportamiento del Consumidor , Conducta Anticonceptiva , Femenino , Estudios de Seguimiento , Geles , Humanos , Perdida de Seguimiento , Persona de Mediana Edad , Nonoxinol/administración & dosificación , Nonoxinol/efectos adversos , Medicamentos sin Prescripción/efectos adversos , Embarazo , Índice de Embarazo , Espermicidas/efectos adversos , Vagina/efectos de los fármacos , Vagina/inmunología , Vagina/metabolismo , Cremas, Espumas y Geles Vaginales/efectos adversos , Vaginitis/inducido químicamente , Vaginitis/inmunología , Adulto Joven
6.
Am J Med Sci ; 344(1): 35-9, 2012 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-22157388

RESUMEN

INTRODUCTION: The objective is to analyze proinflammatory cytokines [interleukin-1ß (IL-1ß), interleukin-6 and tumor necrosis factor-α] and sphingomyelinase in women with bacterial vaginosis (BV), cervicitis and vaginitis. METHODS: From January 2009 to June 2010, human immunodeficiency virus (HIV)-negative, nonpregnant, married women, living with husband, aged 20 to 40 years were recruited from a slum at Hyderabad, India, after taking written consent. One hundred forty-six women including 61 women with BV, 47 women with intermediate flora and 38 women with normal vaginal flora were evaluated for local proinflammatory cytokines and sphingomyelinase. Cervicitis and vaginitis were also analyzed by scoring white blood cells in the cervix and vaginal smears, respectively. RESULTS: Of the 146 women, 50.7% had cervicitis and 19.5% had vaginitis. IL-1ß, tumor necrosis factor-α and interleukin-6 levels were significantly high in women with cervicitis (P < 0.001) and vaginitis (P < 0.001) and IL-1ß in BV (P < 0.005), intermediate flora (P < 0.05) when compared with normal women. High vaginal pH was associated with IL-1ß. Neutral sphingomelinase showed an inverse association (P < 0.05) with cervicitis. Acid sphingomelinase directly correlated with IL-1ß although not significantly. CONCLUSIONS: This study shows proinflammatory response not only in BV but also in women with vaginitis and cervicitis. These conditions are likely to be important in promoting the transmission of HIV-1 and should be the focus of HIV prevention strategies.


Asunto(s)
Bacterias/aislamiento & purificación , Cuello del Útero/metabolismo , Interleucinas/metabolismo , Esfingomielina Fosfodiesterasa/metabolismo , Vagina/metabolismo , Vaginosis Bacteriana/metabolismo , Adulto , Bacterias/clasificación , Cuello del Útero/inmunología , Cuello del Útero/microbiología , Femenino , Seronegatividad para VIH , Humanos , Concentración de Iones de Hidrógeno , India/epidemiología , Interleucina-1beta/metabolismo , Interleucina-6/metabolismo , Factor de Necrosis Tumoral alfa/metabolismo , Cervicitis Uterina/epidemiología , Cervicitis Uterina/inmunología , Cervicitis Uterina/metabolismo , Cervicitis Uterina/microbiología , Vagina/inmunología , Vagina/microbiología , Ducha Vaginal , Vaginitis/epidemiología , Vaginitis/inmunología , Vaginitis/metabolismo , Vaginitis/microbiología , Vaginosis Bacteriana/epidemiología , Vaginosis Bacteriana/inmunología , Vaginosis Bacteriana/microbiología , Adulto Joven
7.
Viral Immunol ; 22(6): 445-9, 2009 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-19951181

RESUMEN

Whether persistent human papillomavirus (HPV) IgG antibodies following natural infection are protective against subsequent infection is unknown. In a cohort of 508 college women followed for 3 y, persistent seropositivity was defined as the presence of type-specific HPV virus-like particle (VLP) antibodies at > or = 2 consecutive visits 1 y apart. Protection from incident infection with any HPV was conferred by persistent antibodies to HPV16 (p = 0.02), HPV31 (p < 0.001), HPV33 (p = 0.03), HPV35 (p = 0.002), HPV52 (p = 0.007), HPV45 (p = 0.003), and HPV53 (p = 0.01). The risk of incident infection with species-specific HPV types was also decreased in women with persistent antibodies to any HPV type in that group, suggesting that exposure to HPV with persistent development of antibody response can be protective, and may explain the decreased efficacy of HPV vaccine in women with prior exposure.


Asunto(s)
Alphapapillomavirus/inmunología , Anticuerpos Antivirales/inmunología , Proteínas de la Cápside/inmunología , Inmunoglobulina G/inmunología , Proteínas Oncogénicas Virales/inmunología , Infecciones por Papillomavirus/inmunología , Cervicitis Uterina/prevención & control , Vaginitis/prevención & control , Interferencia Viral , Adolescente , Adulto , Alphapapillomavirus/clasificación , Sondas de ADN de HPV , ADN Viral/análisis , Femenino , Estudios de Seguimiento , Humanos , Riesgo , Estudios Seroepidemiológicos , Conducta Sexual , Parejas Sexuales , Especificidad de la Especie , Cervicitis Uterina/inmunología , Cervicitis Uterina/virología , Vaginitis/inmunología , Vaginitis/virología , Latencia del Virus , Adulto Joven
8.
Infect Immun ; 74(7): 4282-94, 2006 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-16790803

RESUMEN

This study analyzes the phenotype of vaginal dendritic cells (VDCs), their antigenic presentation and activation of T-cell cytokine secretion, and their protective role in a rat model of Candida vaginitis. Histological observation demonstrated a significant accumulation of OX62(+) VDCs in the mucosal epithelium of Candida albicans-infected rats at the third round of infection. We identified two subsets of OX62(+) VDCs differing in the expression of CD4 molecule in both noninfected and Candida-infected rats. The OX62(+) CD4(+) subset of VDCs displayed a lymphoid cell-like morphology and expressed the T-cell antigen CD5, whereas the OX62(+) CD4(-) VDC subset exhibited a myeloid morphology and was CD5 negative. Candida infection resulted in VDC maturation with enhanced expression of CD80 and CD134L on both CD4(+) and CD4(-) VDC subsets at 2 and 6 weeks after Candida infection. CD5(-) CD4(-) CD86(-) CD80(-) CD134L(+) VDCs from infected, but not noninfected, rats spontaneously released large amounts of interleukin-12 (IL-12) and tumor necrosis factor alpha, whereas all VDC subsets released comparable levels of IL-10 and IL-2 cytokines. Furthermore, OX62(+) VDCs from infected rats primed naïve CD4(+) T-cell proliferation and release of cytokines, including gamma interferon, IL-2, IL-6, and IL-10, in response to staphylococcal enterotoxin B stimulation in vitro. Adoptive transfer of highly purified OX62(+) VDCs from infected rats induced a significant acceleration of fungal clearance compared with that in rats receiving naive VDCs, suggesting a protective role of VDCs in the anti-Candida mucosal immunity. Finally, VDC-mediated protection was associated with their ability to rapidly migrate to the vaginal mucosa and lymph nodes, as assessed by adoptive transfer of OX62(+) VDCs labeled with 5 (and 6-)-carboxyfluorescein diacetate succinimidyl ester.


Asunto(s)
Candida albicans/inmunología , Candidiasis/inmunología , Candidiasis/patología , Células Dendríticas/inmunología , Vaginitis/inmunología , Vaginitis/patología , Traslado Adoptivo , Animales , Candidiasis/prevención & control , Proliferación Celular , Células Cultivadas , Células Dendríticas/patología , Células Dendríticas/trasplante , Femenino , Inmunidad Mucosa , Inmunofenotipificación , Ganglios Linfáticos/inmunología , Ganglios Linfáticos/patología , Ratas , Ratas Wistar , Vagina/inmunología , Vagina/patología , Vaginitis/prevención & control
9.
J Reprod Med ; 50(7): 507-12, 2005 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-16130848

RESUMEN

Chronic inflammation is not an infrequent histologic finding in symptomatic gynecologic patients. It is present in 14.6% of peritoneal biopsies in women with chronic pelvic pain in whom no other cause of pain is evident. It is found in almost all vaginal biopsies in noninfected women with dyspareunia and discharge of vaginal mucosal origin. It represents a local immunologically activated inflammatory disorder. When investigations are car ried out as to whether it is a local representation of a systemic disorder, numerous systemic inflammatory and autoimmune disorders are discovered. A study of chronic pain reveals that the immune system is intimately involved in the production, conduction and exacerbation of pain and of its clinicalfeatures, such as hyperalgesia and allodynia. Immune modification using local steroids and disease-modifying antirheumatic drugs, such as hydroxychloroquine, are known to inhibit inflammatory cells and cytokines, such as interleukin-1, interleukin-6 and tumor necrosis factor, which are responsible for pain and tissue damage. These drugs are found to be effective in the treatment of chronic pelvic pain when of an inflammatory nature and for symptomatic chronic inflammation of the vagina.


Asunto(s)
Peritonitis/inmunología , Vaginitis/inmunología , Antiinflamatorios no Esteroideos/uso terapéutico , Antirreumáticos/uso terapéutico , Enfermedades Autoinmunes/complicaciones , Enfermedad Crónica , Citocinas/biosíntesis , Femenino , Humanos , Dolor Pélvico/etiología , Peritonitis/tratamiento farmacológico , Peritonitis/patología , Esteroides/uso terapéutico , Resultado del Tratamiento , Vaginitis/tratamiento farmacológico , Vaginitis/patología
10.
Antimicrob Agents Chemother ; 49(1): 323-35, 2005 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-15616312

RESUMEN

The sexual transmission of human immunodeficiency virus type 1 (HIV-1) is facilitated by inflammation and related epithelial barrier perturbation. Microbicides for vaginal applications are currently being developed to reduce the risk of HIV-1 transmission. However, little is known about their interference with epithelial immune function. In recent clinical trials, nonoxynol-9 (N-9), a virucide with a long history of intravaginal use as a contraceptive, failed to protect against HIV-1 possibly due to mucosal inflammatory damage. Cellulose acetate 1,2-benzenedicarboxylate, also named CAP (for "controls AIDS pandemic"), is an anti-HIV-1 microbicide selected from pharmaceutical excipients that are regarded as safe for oral administration but have not been assessed for potential effects on inflammatory factors in the vaginal environment. Here we use a sensitive human cell culture system to evaluate proinflammatory profiles of soluble CAP in reference to N-9 and known epithelial activators such as tumor necrosis factor alpha (TNF-alpha) and bacterial lysates. Within 6 h of exposure, TNF-alpha and N-9 triggered NF-kappaB and AP-1/cFos activation and upregulated interleukins and an array of chemokines by vaginal and polarized cervical epithelial cells. The induced proinflammatory status continued after removal of stimuli and was confirmed by enhanced transepithelial neutrophil migration. While sustaining stability and anti-HIV-1 activity in the epithelial environment, CAP did not increase the production of proinflammatory mediators during or after exposure, nor did it modify the epithelial resistance to leukocyte traffic. CAP attenuated some TNF-alpha-induced responses but did not interfere with epithelial cytokine responsiveness to gonococcal determinants. The described system may be useful for predicting proinflammatory side effects of other microbicide candidates for vaginal application.


Asunto(s)
Fármacos Anti-VIH/farmacología , Celulosa/análogos & derivados , Celulosa/farmacología , VIH-1/efectos de los fármacos , Vaginitis/inducido químicamente , Línea Celular , Cuello del Útero/citología , Cuello del Útero/efectos de los fármacos , Cuello del Útero/inmunología , Citocinas/metabolismo , Células Epiteliales/efectos de los fármacos , Células Epiteliales/inmunología , Células Epiteliales/virología , Femenino , Humanos , Nonoxinol/farmacología , Factor de Necrosis Tumoral alfa/farmacología , Vagina/citología , Vagina/efectos de los fármacos , Vagina/inmunología , Vaginitis/inmunología
11.
Med Mycol ; 43(7): 589-601, 2005 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-16396244

RESUMEN

Protective host defense mechanisms against vaginal Candida infections are poorly understood. While cell-mediated immunity (CMI) is the predominant host-defense mechanism against most mucosal Candida infections, no protective role for systemic or local Candida-specific CMI or antibodies has been identified against vaginal candidiasis. Rather, evidence exists for immunoregulation in vaginal tissue, which may inhibit a more profound protective Th1-type response. This study evaluated immunotherapy and gene therapy approaches in the murine model to potentially overcome immunoregulation and promote enhanced protection against vaginal candidiasis. In the first set of studies, the intravaginal and systemic administration of Thl-type cytokines and anti-IL-10 and anti-TGF-beta antibodies failed to enhance protection against a vaginal Candida infection. In a second set of studies, the novel intravaginal administration of Adenoviruses encoding Th1-type cytokines (IFN-gamma and IL-12) and the chemokine, MCP-1, showed substantial, but transient (24 h) expression of each in vaginal tissue and draining lymph nodes, even with a second administration. Unfortunately, treatment with these Adenoviral vectors did not enhance protection against experimental vaginitis. Construction of a new vector encoding IFN-gamma with a stronger promoter produced substantial IFN-gamma in vitro, but lower amounts in vivo and no extended expression. Taken together, while gene therapy can be used to induce cytokine expression in vaginal tissue, there appear to be strong regulatory mechanisms that additional manipulations or alternative approaches will have to overcome if protection against vaginitis is to be enhanced.


Asunto(s)
Candida/inmunología , Candidiasis Vulvovaginal/inmunología , Candidiasis/terapia , Citocinas/inmunología , Inmunoterapia , Vaginitis/terapia , Animales , Candidiasis/inmunología , Candidiasis Vulvovaginal/terapia , Citocinas/análisis , Modelos Animales de Enfermedad , Femenino , Interferón gamma/análisis , Ratones , Ratones Endogámicos CBA , Vaginitis/inmunología , Vaginitis/microbiología
12.
J Immunol ; 173(3): 1908-13, 2004 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-15265924

RESUMEN

The members of the lymphotoxin (LT) family of molecules play a critical role in lymphoid organogenesis. Whereas LT alpha-deficient mice lack all lymph nodes and Peyer's patches, mice deficient in LT beta retain mesenteric lymph nodes and cervical lymph nodes, suggesting that an LT beta-independent pathway exists for the generation of mucosal lymph nodes. In this study, we describe the presence of a lymph node in LT beta-deficient mice responsible for draining the genital mucosa. In the majority of LT beta-deficient mice, a lymph node was found near the iliac artery, slightly misplaced from the site of the sacral lymph node in wild-type mice. The sacral lymph node of the LT beta-deficient mice, as well as that of the wild-type mice, expressed the mucosal addressin cell adhesion molecule-1 similar to the mesenteric lymph node. Following intravaginal infection with HSV type 2, activated dendritic cells capable of stimulating a Th1 response were found in this sacral lymph node. Furthermore, normal HSV-2-specific IgG responses were generated in the LT beta-deficient mice following intravaginal HSV-2 infection even in the absence of the spleen. Therefore, an LT beta-independent pathway exists for the development of a lymph node associated with the genital mucosa, and such a lymph node serves to generate potent immune responses against viral challenge.


Asunto(s)
Herpes Genital/inmunología , Herpesvirus Humano 2/inmunología , Inmunoglobulinas/análisis , Ganglios Linfáticos/inmunología , Linfotoxina-alfa/deficiencia , Proteínas de la Membrana/deficiencia , Mucoproteínas/análisis , Vaginitis/inmunología , Animales , Anticuerpos Antivirales/biosíntesis , Anticuerpos Antivirales/inmunología , Linfocitos T CD4-Positivos/inmunología , Moléculas de Adhesión Celular , Células Dendríticas/inmunología , Femenino , Inmunoglobulina G/biosíntesis , Inmunoglobulina G/inmunología , Ganglios Linfáticos/química , Ganglios Linfáticos/patología , Activación de Linfocitos , Linfotoxina-alfa/genética , Linfotoxina beta , Proteínas de la Membrana/genética , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Región Sacrococcígea , Esplenectomía , Especificidad del Receptor de Antígeno de Linfocitos T , Células TH1/inmunología
13.
Sex Transm Dis ; 29(10): 597-605, 2002 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-12370527

RESUMEN

BACKGROUND: Because topical microbicides designed to prevent the spread of sexually transmitted diseases may be applied frequently, it is important to ensure product safety as well as efficacy. A murine model was developed to test for induction of inflammatory responses following application of candidate microbicides. GOAL: A comparison was made of the induction of inflammation following vaginal application of detergent-based and sulfated polymer-based microbicides. STUDY DESIGN: Vaginal leukocytes were collected, identified, and quantified following microbicide application to detect the entry of inflammatory leukocytes into the vaginal lumen. RESULTS: Large numbers of neutrophils and macrophages entered the vaginal lumen following a single application of detergent-based microbicides. No significant increase in vaginal leukocytes was detected following a single or repeated application of sulfated polymer-based microbicides. CONCLUSION: Application of sulfated polymer-based microbicides was less likely to result in inflammatory responses than was application of detergent-based compounds. This murine model should prove useful as part of a screening process to prioritize candidate microbicides before clinical trial.


Asunto(s)
Antiinfecciosos Locales/administración & dosificación , Macrófagos/patología , Neutrófilos/patología , Nonoxinol/administración & dosificación , Dodecil Sulfato de Sodio/administración & dosificación , Vagina/efectos de los fármacos , Vaginitis/inducido químicamente , Administración Intravaginal , Animales , Recuento de Células , Evaluación Preclínica de Medicamentos/métodos , Femenino , Citometría de Flujo , Ratones , Modelos Animales , Vagina/inmunología , Cremas, Espumas y Geles Vaginales/administración & dosificación , Vaginitis/inmunología
14.
Mod Pathol ; 14(12): 1263-9, 2001 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11743049

RESUMEN

In Thailand, the predominant HIV subtype is E, rather than Subtype B as in North America and Europe, and the predominant mode of transmission is heterosexual contact. Subtype E has the ability to replicate in vitro in Langerhans cells. We hypothesized that this cell type might constitute a reservoir for the HIV virus in vaginal mucosa of asymptomatic carriers. To examine this hypothesis, we compared vaginal tissue histology in HIV-1-seropositive cases with seronegative cases and determined the immunophenotype of HIV-1-infected cells, their numbers, and their distribution in vaginal mucosa. Vaginal biopsies were performed at four different sites from six asymptomatic HIV-1 Subtype E-infected persons and from six seronegative cases at necropsy and examined histologically. Immunophenotyping was performed using immunoperoxidase for Gag p24 HIV, CD3, CD20, CD68, CD1a, S-100 and p55 antigens and by double labeling, combining immunoperoxidase with alkaline phosphatase using pairs of the above antigens. Twenty of twenty-four vaginal biopsies (83.3%) from HIV-seropositive cases showed definite inflammation compared to five of twenty-four vaginal necropsies (20.8%) from HIV-seronegative cases. One third of HIV-seropositive biopsies (8/24) demonstrated p24-positive cells in the epithelium, whereas three-fourths (18/24) of the biopsies revealed p24-positive cells in the lamina propria. All seropositive patients showed positive cells in at least one biopsy, but not all biopsies contained positive cells. Infected cells were more frequently observed at sites of greater inflammation. The dendritic cell count in HIV-seropositive vaginal epithelium was significantly higher than that observed in the seronegative cases (P =.004). The majority of p24-positive cells in the vaginal epithelium were Langerhans cells (CD1a+/S-100+), whereas in the lamina propria, about half of p24-positive cells were Langerhans-related dendritic cells (p55+ and S-100+) and half were T lymphocytes. In conclusion, the increased propensity for heterosexual transmission of Subtype E may be related to vaginal inflammation, leading to the accumulation of Langerhans cells and related dendritic cells which, once infected with HIV, can act as a reservoir for further virus transmission.


Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/patología , Reservorios de Enfermedades , VIH-1/crecimiento & desarrollo , Células de Langerhans/patología , Vagina/patología , Síndrome de Inmunodeficiencia Adquirida/inmunología , Síndrome de Inmunodeficiencia Adquirida/transmisión , Síndrome de Inmunodeficiencia Adquirida/virología , Antígenos CD/análisis , Biomarcadores/análisis , Recuento de Células , Femenino , Técnica del Anticuerpo Fluorescente Indirecta , Proteína p24 del Núcleo del VIH/análisis , Seropositividad para VIH , VIH-1/clasificación , VIH-1/genética , VIH-1/aislamiento & purificación , Humanos , Técnicas para Inmunoenzimas , Inmunofenotipificación , Células de Langerhans/inmunología , Células de Langerhans/virología , Membrana Mucosa/inmunología , Membrana Mucosa/patología , Membrana Mucosa/virología , Tailandia , Vagina/inmunología , Vagina/virología , Vaginitis/inmunología , Vaginitis/patología , Vaginitis/virología
15.
Virology ; 269(2): 451-61, 2000 Apr 10.
Artículo en Inglés | MEDLINE | ID: mdl-10753723

RESUMEN

Rabbit oral papillomavirus (ROPV) infects mucosal tissues of domestic rabbits. The viral genomic sequence has been determined and the most related papillomavirus type was the cutaneous cottontail rabbit papillomavirus (CRPV). Homologies between the open reading frames (ORFs) of ROPV and CRPV, however, ranged from 68% amino acid identity for L1 to only 23% identity for E4. Shared features unique to the two rabbit viruses included a large E6 ORF and a small E8 ORF that overlapped the E6 ORF. Serological responses to ROPV L1 viruslike particles (VLPs) were detected in rabbits infected at either the genital or oral mucosa with ROPV. The antibody response was specific to intact ROPV L1 VLP antigen, was first detected at the time of late regression, and persisted at high levels for several months after complete regression. Both oral and genital lesions regressed spontaneously, accompanied by a heavy infiltrate of lymphocytes. ROPV infection of rabbit genital mucosa is a useful model to study host immunological responses to genital papillomavirus infections.


Asunto(s)
Papillomavirus del Conejo de Rabo Blanco/genética , Genoma Viral , Infecciones por Papillomavirus/genética , Infecciones Tumorales por Virus/genética , Animales , Balanitis/inmunología , Balanitis/virología , Secuencia de Bases , Ensayo de Inmunoadsorción Enzimática , Femenino , Masculino , Datos de Secuencia Molecular , Sistemas de Lectura Abierta , Infecciones por Papillomavirus/inmunología , Conejos , Estomatitis/inmunología , Estomatitis/virología , Infecciones Tumorales por Virus/inmunología , Vaginitis/inmunología , Vaginitis/virología
16.
Artículo en Inglés | MEDLINE | ID: mdl-9715841

RESUMEN

In this cross-sectional study, 53 cervicovaginal lavage samples (CVL) from 41 women were analyzed for the chemokines interleukin-8 (IL-8), regulated-on-activation normal T-expressed and secreted (RANTES) factor, and macrophage inflammatory protein-1alpha (MIP-1alpha) by enzyme-linked immunosorbent assay (ELISA). IL-8 was detected in 81% of CVL, whereas RANTES was detected in 32%, and MIP-1alpha in 15% of the CVL. The mean levels of IL-8, RANTES, and MIP-1alpha in positive samples were 396 pg/ml, 102 pg/ml, and 34 pg/ml, respectively. IL-8 levels correlated positively with IL-1beta and IgG in a subset of CVL samples. RANTES levels correlated positively with complement protein levels. Additionally, the levels of RANTES, but not MIP-1alpha, reached levels reported in previous studies of the effects of beta chemokines to inhibit HIV replication. These results suggest that measuring chemokines in CVL specimens can provide important information regarding immune responses in the genital tract.


Asunto(s)
Cuello del Útero/inmunología , Citocinas/análisis , Seronegatividad para VIH/inmunología , Seropositividad para VIH/inmunología , Vagina/inmunología , Quimiocina CCL3 , Quimiocina CCL4 , Quimiocina CCL5/análisis , Estudios Transversales , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Interleucina-8/análisis , Proteínas Inflamatorias de Macrófagos/análisis , Papillomaviridae , Infecciones por Papillomavirus/inmunología , Infecciones por Papillomavirus/patología , Irrigación Terapéutica , Infecciones Tumorales por Virus/inmunología , Infecciones Tumorales por Virus/patología , Vagina/patología , Vaginitis/inmunología , Vaginitis/patología
17.
J Immunol ; 160(12): 5998-6003, 1998 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-9637514

RESUMEN

This study evaluates whether the vaginal mucosal surface of immunized mice can prevent invasion by herpes simplex virus (HSV) and aims to identify immune components that affect immunity after challenge at the vaginal mucosa. Despite the induction of both IgA and IgG vaginal Ab following immunization with recombinant vaccinia virus vectors expressing either glycoproteins B or D, viral infection occurred in most animals even after minimal viral dose challenge. Challenged immune animals, including those genetically unable to generate anti-HSV Ab, survived and showed few if any clinical signs of infection. Experiments with T cell subtype knockout animals and depletion with T cell subset-specific MAb indicated that immunity following vaginal challenge was principally dependent on the function of CD4+ T cells. Our results indicate that anti-HSV vaccines may not provide barrier immunity at the vaginal mucosal site but may be adequate to minimize clinical expression of disease.


Asunto(s)
Herpes Simple/inmunología , Administración Intranasal , Animales , Anticuerpos Antivirales/biosíntesis , Linfocitos B/inmunología , Linfocitos T CD4-Positivos/inmunología , Femenino , Inmunidad Mucosa , Inmunoglobulina A/biosíntesis , Inmunoglobulina G/biosíntesis , Ratones , Ratones Endogámicos BALB C , Proteínas Recombinantes/inmunología , Virus Vaccinia , Vaginitis/inmunología , Vaginitis/virología , Proteínas del Envoltorio Viral/inmunología , Vacunas Virales/administración & dosificación , Vacunas Virales/inmunología
18.
Med Microbiol Immunol ; 183(2): 87-94, 1994 May.
Artículo en Inglés | MEDLINE | ID: mdl-7935163

RESUMEN

Primary infections with herpes simplex virus type 2 (HSV-2) suppress the antibody response to secondary HSV-1 and -2 infections in the BALB/c mouse. In contrast, a challenge by the i.p. route using a vaccinia virus-HSV-1 glycoprotein B (VV gB1) recombinant induces a significant enhancement of the antibody response. This booster reaction is also observed if a challenge with a formalin-inactivated HSV-1 vaccine is performed. Although no or low humoral and vaginal antibodies are detectable after a single i.p. infection with the VV gB1 recombinant or the HSV-1 vaccine, protection against vaginal challenge with HSV-2 is induced. This points to the important role of cellular immunity for vaginal infections.


Asunto(s)
Herpes Genital/inmunología , Herpesvirus Humano 1/inmunología , Herpesvirus Humano 2/inmunología , Tolerancia Inmunológica , Proteínas del Envoltorio Viral/inmunología , Vacunas Virales/inmunología , Animales , Anticuerpos Antivirales/inmunología , Femenino , Herpes Genital/prevención & control , Herpesvirus Humano 1/genética , Ratones , Ratones Endogámicos BALB C , Proteínas Recombinantes de Fusión/inmunología , Vacunas de Productos Inactivados , Virus Vaccinia/genética , Vagina/virología , Vaginitis/inmunología , Vaginitis/prevención & control , Proteínas del Envoltorio Viral/genética , Replicación Viral
19.
Arch Gynecol Obstet ; 251(4): 159-64, 1992.
Artículo en Inglés | MEDLINE | ID: mdl-1503506

RESUMEN

A community oriented intervention program was initiated in 1985 in 12 rural communities in southern Israel to identify and treat women of reproductive age with markers of Chlamydia trachomatis (CT) infection. Among 860 women tested, 21 (2.4%) had CT IgG antibody titers greater than or equal to 128, or CT IgA antibody titers greater than or equal to 16, and 9 of these women had positive cultures for CT. The 21 women, as well as their male partners, received specific anti-CT treatment, and were followed up for 5 years to assess obstetric complications, and to evaluate the effectiveness of treatment. In 9 women positive cultures became negative. In 13 out of the 17 cases with sequential follow-up a four fold decrease in IgG specific antibody titers was observed. Yet, in all but two of the cases, IgA specific antibody titers remained greater than or equal to 16.


Asunto(s)
Anticuerpos Antibacterianos/análisis , Infecciones por Chlamydia/prevención & control , Chlamydia trachomatis/inmunología , Doxiciclina/uso terapéutico , Enfermedad Inflamatoria Pélvica/prevención & control , Complicaciones Infecciosas del Embarazo/prevención & control , Población Rural , Frotis Vaginal , Vaginitis/prevención & control , Adulto , Infecciones por Chlamydia/inmunología , Femenino , Estudios de Seguimiento , Humanos , Inmunoglobulina A/análisis , Inmunoglobulina G/análisis , Enfermedad Inflamatoria Pélvica/inmunología , Embarazo , Complicaciones Infecciosas del Embarazo/inmunología , Vaginitis/inmunología
20.
Am J Obstet Gynecol ; 164(5 Pt 1): 1351-4, 1991 May.
Artículo en Inglés | MEDLINE | ID: mdl-2035579

RESUMEN

Recurrent vaginal infections caused by Candida albicans are associated with decreased cell-mediated immune responses. We report that circulating progesterone levels and variations between persons in the activity of their monocytes are two of the factors that influence the extent of lymphocyte proliferation in response to C. albicans. With the use of peripheral blood mononuclear cells from five men and four women, removal of the monocytes increased the lymphocyte response to C. albicans antigens in eight persons. The percentage increase in proliferation was inversely proportional to the proliferative response observed when the monocytes were present, suggesting that differences existed between persons in the ability of their monocytes to down regulate the response. An approximate 50% decrease in C. albicans-induced lymphocyte proliferation was observed in the presence of luteal-phase levels (25 ng/ml), as opposed to proliferative-phase levels (0.15 ng/ml) of progesterone. Monocyte removal obviated the ability of 25 ng/ml progesterone to inhibit this response, suggesting that progesterone inhibited lymphocyte proliferation through a monocyte-dependent mechanism. Thus fluctuations in a woman's monocyte activity in response to genetic, hormonal, or environmental factors may influence her ability to mount an effective cell-mediated immune response to C. albicans.


Asunto(s)
Candida albicans/inmunología , Candidiasis/inmunología , Monocitos/inmunología , Progesterona/farmacología , Vaginitis/inmunología , División Celular/efectos de los fármacos , Femenino , Humanos , Inmunidad Celular/efectos de los fármacos , Linfocitos/citología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA